



Our STN: BL 125108/1010

SUPPLEMENT APPROVAL

Merck Sharp & Dohme Corp.
Attention: Louise Saldutti, Ph.D.
351 N. Sumneytown Pike
P.O. Box 1000
UG2D-68
North Wales, PA 19454

April 13, 2021

Dear Dr. Saldutti:

We have approved your request submitted and received on October 21, 2020, to supplement your Biologics License Application (BLA) under section 351(a) of the Public Health Service Act for Measles, Mumps, Rubella and Varicella Virus Vaccine Live (ProQuad) manufactured at the West Point, PA facility to include newly developed US Patient Package Inserts (PPIs) for the refrigerator-stable and frozen formulations of ProQuad and updated US Package Inserts for the refrigerator-stable and frozen formulations of ProQuad that reference the new PPIs.

LABELING

We hereby approve the Patient Package Insert labeling submitted under amendment 2, dated March 30, 2021, and the Package Insert labeling submitted under amendment 3, dated April 8, 2021.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, please submit the final content of labeling (21 CFR 601.14) in Structured Product Labeling (SPL) format via the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the Package Insert and Patient Package Insert, submitted on March 24 and March 30, respectively. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

All final labeling should be submitted as Product Correspondence to this BLA,

STN 125108, at the time of use and include implementation information on Form FDA 356h.

ADVERTISING AND PROMOTIONAL LABELING

You may submit two draft copies of the proposed introductory advertising and promotional labeling with Form FDA 2253 to the Advertising and Promotional Labeling Branch at the following address:

Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Ave.
WO71–G112
Silver Spring, MD 20993-0002

You must submit copies of your final advertising and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f)(4)).

All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims (21 CFR 202.1(e)(6)).

Two draft copies of the proposed introductory advertising or promotional labeling may be voluntarily submitted for advisory comment with a completed Form FDA 2253 to the Advertising and Promotional Labeling Branch at the following address:

Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Ave.
WO71–G112
Silver Spring, MD 20993-0002

Please submit an amendment to all pending supplemental applications for this BLA that include revised labeling incorporating a revised content of labeling that includes these changes.

We will include information contained in the above-referenced supplement in your BLA file.

Sincerely,

Doran L. Fink, M.D., Ph.D.
Deputy Director - Clinical
Division of Vaccines and
Related Products Applications
Office of Vaccines
Research and Review
Center for Biologics
Evaluation and Research